Chairman of the board since 2016.
Stefan Tilk is currently the Vice Chairman and group CEO at NEVS AB. He has a Master’s degree in Engineering Physics from Chalmers University of Technology and studied Business Administration in Barcelona School of Economics. Stefan has extensive experience, leading and developing companies as a CEO, including Geveko AB and Elof Hanson Group. Former Senior Executive Vice President for both Volvo Buses and Volvo Trucks, former Executive Vice President at Coor, Stefan has a strong business development background, skilled in negotiation, business planning, operations management, sales, and international business.
Board member since 2015.
Owe is the CEO of Oblique Therapeutics and Senior Group Leader at the Karolinska Institute. After completing a PhD in chemistry from Gothenburg University, he completed two years of postdoctoral studies at Stanford University. Former Global VP of R&D at Sanofi, former President of R&D at Piramal Healthcare, entrepreneur/founder and inventor of six biotech companies, Owe has over 20 years of experience in the pharma and biotech industry. Holder of more than 75 patents, author of hundreds of research articles, he is a pioneer in the fields of single-cell biology and biophysics with several products on the global market.
Gavin D. M. Jeffries
Board member since 2012.
Born in 1980.
Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration.
Daniel T. Chiu
Board member since 2017.
Daniel has been Professor of Chemistry and Bioengineering at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University. Scientific Founder of multiple Life Sciences/Biomedical companies across Asia, Europe, and U.S.A Member/Chair of numerous advisory and review panels for government and industry, he is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is the inventor on over 60 issued patents.
Board member since 2017.
Born in 1975.
Master of Laws, University of Gothenburg.
Carl is an experienced and recognized lawyer at MAQS’ Gothenburg office. He has extensive experience of commercial agreements, including ones relating to cooperation, commission, and purchasing, as well as to terms and conditions. He specializes in sports, media, and the entertainment industry in which he has worked for over ten years, in addition to being the sports director of the football club BK Häcken four years. Considering Carl’s dual legal and managerial background, has led him to assist many boards in an advisory manner, or to join them as a member or a chairman.
Regina Fritsche Danielson
Board member since 2022
PhD in Cardiovascular Physiology and Pharmacology from the University of Gothenburg.
Regina is Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism at AstraZeneca, leading drug development from target discovery through clinical proof-of-concept in the areas of unmet medical need and cardiovascular and metabolic diseases. The main focus of Danielson's research activities is to develop new therapies which can stop disease progression and/or cure disease, with regenerative approaches and personalized medicine as core strategic elements. Regina is a steering committee member of several strategic research collaborations, as well as the British Heart Foundation Centre for Research Excellence (CRE) Cambridge, the Physiological Systems Domain Panel, Medical Research Council (MRC).